In an interview with Bloomberg News, Eli Lilly Chief Financial Officer Lucas Montarce said that the Indiana-based pharma giant remains on track for a potential FDA approval of its obesity pill, ...
Strong subscription revenue growth, record gross margins, and durable cash generation fuel a 'Buy' rating for Q2. Key metrics to watch in Q2's upcoming earnings are subscription ARR growth, contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results